Gilead Sciences Inc. GILD
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · gilead.com
Gilead Sciences, Inc. is an American biopharmaceutical company that researches, develops, and commercializes medicines in areas of unmet medical need, with a primary focus on antiviral treatments for HIV/AIDS, hepatitis B, hepatitis C, and COVID-19. The company's commercial portfolio includes leading drugs such as Biktarvy and Descovy for HIV and Veklury (remdesivir) for COVID-19, and has expanded into oncology and inflammatory diseases through acquisitions.
Key ratios
FreeCashFlowOnSale TTM 0.32
FreeCashFlowOnSale 2025 0.32
FreeCashFlowOnSale 2024 0.36
FreeCashFlowOnSale 2023 0.27
NetIncomeMargin TTM 0.29
NetIncomeMargin 2025 0.29
NetIncomeMargin 2024 0.02
NetIncomeMargin 2023 0.21
ReturnOnAssets TTM 0.13
ReturnOnAssets 2025 0.13
ReturnOnAssets 2024 0.11
ReturnOnAssets 2023 0.09
ReturnOnEquity TTM 0.41
ReturnOnEquity 2025 0.41
ReturnOnEquity 2024 0.02
ReturnOnEquity 2023 0.26
Recent news
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
2026-06-15 · Gilead Sciences
Gilead Sciences Announces First Quarter Financial Results
2026-05-07 · Gilead Sciences